Last $19.88 USD
Change Today 0.00 / 0.00%
Volume 0.0
HLUKF On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
Stuttgart
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (HLUKF) Snapshot

Open
$19.88
Previous Close
$19.88
Day High
$19.88
Day Low
$19.88
52 Week High
04/1/14 - $31.33
52 Week Low
02/9/15 - $18.64
Market Cap
3.9B
Average Volume 10 Days
100.1
EPS TTM
--
Shares Outstanding
196.4M
EX-Date
03/26/15
P/E TM
--
Dividend
--
Dividend Yield
2.56%
Current Stock Chart for H LUNDBECK A/S (HLUKF)

Related News

No related news articles were found.

h lundbeck a/s (HLUKF) Details

H. Lundbeck A/S researches, develops, produces, and sells pharmaceuticals for the treatment of brain disorders in Denmark and internationally. The company offers pharmaceutical products for the treatment of schizophrenia, major depressive disorder, symptomatic neurogenic orthostatic hypotension, lennox-gastaut syndrome, and alcohol dependence. It also offers other products for the treatment of Alzheimer’s disease, depression and anxiety, Parkinson’s disease, chorea associated with Huntington’s disease, relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, manic episodes associated with bipolar 1 disorder, and refractory complex partial seizures. In addition, the company is involved in the development of Brexpiprazole, a novel investigational psychotherapeutic compound; and Idalopirdine, a potent and selective 5-HT6 receptor antagonist that are in Phase III clinical trails. It has strategic alliances with various companies, including Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Valby, Denmark.

5,811 Employees
Last Reported Date: 02/5/15
Founded in 1915

h lundbeck a/s (HLUKF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (HLUKF) Key Developments

H. Lundbeck A/S, 2014 Earnings Call, Feb 05, 2015

H. Lundbeck A/S, 2014 Earnings Call, Feb 05, 2015

H. Lundbeck A/S Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

H. Lundbeck A/S announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of DKK 838 million compared to profit from operations of DKK 68 million last year. Revenue was DKK 3,247 million against DKK 3,587 million a year ago. Loss before tax was DKK 869 million against profit before tax of DKK 38 million a year ago. Net loss was DKK 633 million or DKK 3.22 per diluted share against net profit of DKK 23 million or DKK 0.12 per diluted share a year ago. Cash flows from operating activities were DKK 538 million compared to DKK 1,529 million a year ago. Investments in intangible assets and property, plant and equipment were DKK 155 million compared to DKK 610 million a year ago. Cash flow per share was DKK 2.74 compared to DKK 7.79 a year ago. Return on equity was negative of 4.6% against 0.2% a year ago For the year, the company reported revenue of DKK 13,468 million compared to DKK 15,258 million a year ago. Profit from operations was DKK 99 million compared to DKK 1,599 million a year ago. Loss before tax was DKK 56 million compared to profit before tax of DKK 1,472 million a year ago. Net loss was DKK 153 million compared to profit of DKK 855 million a year ago. Diluted loss per share was DKK 0.78 compared to diluted earnings per share of DKK 4.36 a year ago. Cash flows from operating activities were DKK 1,610 million compared to DKK 3,760 million a year ago. Investments in intangible assets and property, plant and equipment were DKK 1,541 million compared to DKK 1,510 million a year ago. Cash flow per share was DKK 19.17 compared to DKK 10.76 a year ago. Cash flow per share was DKK 8.2 compared to DKK 19.16 a year ago. Return on equity was negative of 1.1% against 6.4% a year ago. Core EBIT was DKK 1,228 million compared to DKK 2,282 million a year ago. Core EPS was DKK 3.21 compared to DKK 8.02 a year ago. For the fiscal year 2015, Lundbeck is expecting constant exchange rate revenue to be in the range DKK 13.2-13.7 billion. Lundbeck still expects core profit from operations (core EBIT) in constant exchange rate to be around DKK 0 for 2015.

Lundbeck Proposes No Dividend Payout for 2014

Lundbeck at the Annual General Meeting to be held on 25 March 2015 proposed no dividend payout for 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HLUKF:US $19.88 USD 0.00

HLUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $22.99 USD -0.07
Emergent Biosolutions Inc $28.87 USD -1.23
Lupin Ltd 1,787 INR -15.10
Nektar Therapeutics $12.94 USD -0.09
Salix Pharmaceuticals Ltd $156.50 USD -0.38
View Industry Companies
 

Industry Analysis

HLUKF

Industry Average

Valuation HLUKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.